LANGUAGES PRESS RELEASES General News Financial News 2021 Download 2021/10/26 Adocia announces 2021 third quarter financial results and a financing of €7 million 2021/10/14 ADOCIA’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial in China 2021/09/21 ADOCIA announces Oral Presentation Reviewing M1Pram (ADO09) at the occasion of the 57th Annual Meeting of EASD 2021/09/10 Adocia To Participate in the H.C. Wainwright 23rd Annual Global Investment Conference 2021/09/07 ADOCIA Announces First Half 2021 Financial Results and Provides an Update on Activities 2021/08/23 Number of shares and voting rights of ADOCIA as of July 31st, 2021 2021/07/29 Adocia Announces Half year report on Adocia’s liquidity agreement with Kepler Capital Markets 2021/07/22 ADOCIA Announces Second Quarter 2021 Financial Results 2021/06/29 ADOCIA Initiates BC LisPram Phase 1 Clinical Trial in Pump for People with Type 1 Diabetes 2021/06/15 ADOCIA Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 81st Scientific Sessions 2021/06/08 ADOCIA confirms its eligibility for the PEA–PME 2021/06/02 ADOCIA Presents Clinical Results on M1Pram at the 14th International Conference on ATTD 2021 2021/06/01 ADOCIA reinforces its board of directors with the appointment of three new independent members. 2021/05/26 ADOCIA Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps 2021/05/11 ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021 2021/04/21 ADOCIA Announces the Release of its Universal Registration Document for the Year 2020 2021/04/21 ADOCIA Announces First Quarter 2021 Financial Results 2021/03/18 ADOCIA Announces Financial Results 2020 And Provides Corporate Update. 2021/03/10 Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes 2021/01/25 Adocia Announces Positive Clinical Results Confirming the Ultra-Rapid Profile of a BioChaperone® Lispro Formulation Containing Insulin from Partner Tonghua Dongbao 2021/01/11 Adocia Files Patent on a Hydrogel Scaffold for Cell Therapy in the Treatment of Type 1 Diabetes 2020 Download 2020/12/21 Adocia announces its financial calendar for 2021 2020/10/20 Adocia Announces Third Quarter 2020 Financial Results 2020/09/22 Adocia announces a Video Conference to Present a Corporate Update Wednesday, September 23rd, 2020 2020/09/15 Adocia announces Positive Topline Results of Phase 1b Study for M1Pram in People with type 1 Diabetes. 2020/09/07 September 15th: Adocia to Present at H.C. Wainwright Global Investment Conference (Virtual Event) 2020/09/03 September 10th: Adocia Oral Presentation at the Annual Congress of the Société Francophone du Diabète (SFD). 2020/08/18 Adocia was granted a State-guaranteed loan (PGE) for EUR 7 million associated with a rescheduling of the loan terms contracted in 2019. 2020/07/30 Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S 2020/07/20 Adocia Announces First Half 2020 Financial Results 2020/06/08 Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtual experience 2020/04/23 Adocia announces positive topline results of the exploratory Phase 1b study of ADO09 (M1Pram) in people with type 1 diabetes 2020/04/23 Adocia announces the release of its Universal Reference Document for the year 2019 2020/04/20 Adocia to hold its annual shareholders’ meeting on May 28th, 2020 in Lyon 2020/04/14 Adocia announces first quarter 2020 financial results and update on the impact of COVID-19 2020/03/12 Adocia Announces Full Year 2019 Financial Results 2019 Download 2019/12/17 Adocia announces its financial calendar for 2020 2019/12/11 Adocia Announces the Subscription of the Second Tranche of the Financing Line obtained from IPF Partners 2019/10/22 Adocia Announces Third Quarter 2019 Financial Results 2019/10/14 Adocia obtains additional financial resources to accelerate its growth 2019/09/30 Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case 2019/09/10 Adocia Announces Oral Presentation Covering ADO09, its pramlintide insulin coformulation, at EASD 2019/08/23 Adocia announces the decision of the American Arbitration Association Tribunal 2019/07/17 Adocia Presents First Half 2019 Financial Results 2019/06/06 Adocia initiates a 3-week Phase 1b study of ADO09, a co-formulation of pramlintide and mealtime insulin, in people with type 1 diabetes 2019/06/04 Adocia Announces Scientific Data Presentations at the American Diabetes Association® 79th Scientific Sessions 2019/04/15 Adocia announces the release of its Reference Document for the year 2018 2019/04/15 Adocia announces first quarter 2019 financial results: cash position and revenue 2019/04/10 Adocia announces topline results for the first clinical study of ADO09, a new co-formulation of pramlintide and a prandial insulin 2019/04/10 Adocia to hold its annual shareholders’ meeting on May 16, 2019 in Paris 2019/03/13 Adocia Announces its Financial Results for 2018: Higher Revenue and Reinforced Cash Position 2019/02/12 Adocia to Present New Clinical Data on BioChaperone® Technology at ATTD 2019 2019/01/16 Adocia confirms its financial calendar for 2019 2019/01/03 PR: Adocia Announces a Clinical Trial Evaluating BioChaperone® Lispro and Other Rapid-Acting Insulin Analogs Using iLetTM Bionic Pancreas 2018 Download 2018/12/20 Adocia announces its financial calendar for 2019 2018/10/23 Adocia Announces Third Quarter 2018 Financial Results 2018/10/11 Adocia informs about a civil action filed by Eli Lilly 2018/10/05 Adocia to hold an ordinary shareholders’ meeting on November 9, 2018 in Lyon 2018/09/26 Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) 2018/09/05 Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes 2018/08/30 Adocia Announces Update to Second Arbitration Against Eli Lilly & Company 2018/08/21 Number of shares and voting rights of ADOCIA as of July 31, 2018 2018/08/08 American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly 2018/07/25 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets 2018/07/18 Adocia Presents First Half 2018 Financial Results 2018/06/14 Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions 2018/06/05 Adocia to Participate in the Jefferies 2018 Global Healthcare Conference 2018/06/01 Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine 2018/05/02 Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao 2018/04/26 Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China. 2018/04/19 Adocia announces the release of its Reference Document for the year 2017 2018/04/16 Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes 2018/04/16 Adocia announces first quarter 2018 financial results: Cash position and revenue 2018/04/09 Adocia to hold its annual shareholders’ meeting on May 17, 2018 in Lyon 2018/03/19 ADOCIA announced its financial results for 2017 and its perspectives for 2018 2018/02/09 Adocia to Present at the 2018 BIO CEO & Investor Conference in New York 2018/02/06 Adocia Files Additional Arbitration Claims Against Eli Lilly & Company 2018/01/25 Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes 2018/01/08 Adocia announces its financial calendar for 2018 2018/01/04 Adocia announces expanded use of BioChaperone® beyond diabetes 2017 Download 2017/12/06 Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes 2017/11/20 Adocia Reports Topline Results of BioChaperone® Glucagon Phase 1 Study 2017/10/11 Adocia announces financial results for the third quarter 2017 2017/09/05 Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes 2017/07/26 Adocia announces appointment of Dr. Stanislav Glezer as Chief Medical Officer 2017/07/19 Adocia presents first half 2017 financial results 2017/06/07 Adocia Initiates a Phase 1b Clinical Study on the Dose-Proportionality of BioChaperone® Combo in People with Type 2 Diabetes 2017/06/06 Adocia Announces Positive Topline Results from a Meal-Test Clinical Study of BioChaperone® Combo in People with Type 2 Diabetes 2017/06/01 Adocia initiates a study comparing ultra-rapid insulin BioChaperone® Lispro U100 with Fiasp® and Novolog® administered with an insulin pump 2017/06/01 Adocia Launches First-in-Man Clinical Study of BioChaperone® Glucagon 2017/05/30 Adocia Announces Six Data Presentations at the American Diabetes Association® 77th Scientific Sessions 2017/05/30 Adocia to Present at the Jefferies 2017 Global Healthcare Conference in New York 2017/05/19 Adocia to hold its annual shareholders’ meeting on June 27, 2017 in Paris 2017/04/18 Adocia announces the release of its Reference Document, containing the Annual Financial Report and the Management Report, for the year 2016 2017/04/18 Adocia announces first quarter 2017 financial results 2017/04/13 Number of shares and voting rights of Adocia as of March 31, 2017 2017/03/21 ADOCIA confirms its eligibility for the PEA – PME 2017/03/13 Number of shares and voting rights of ADOCIA as of February 28, 2017 2017/03/07 ADOCIA announced its financial results for 2016 and its perspectives for 2017 2017/02/14 Adocia announces its revenue and cash position for 2016 2017/02/13 Adocia to Present at the Leerink Partners 6th Annual Global Healthcare Conference 2017/01/27 Adocia to hold conference call on Monday January 30, 2017 2017/01/27 Adocia announces the termination by Eli Lilly of the collaboration on BioChaperone Lispro 2017/01/25 Adocia to hold conference call providing an update on its programs 2017/01/19 Adocia announces the transformation of its business model to increase the value of its projects 2017/01/05 Adocia announces two new multi-hormonal combination projects for the treatment of type 1 diabetes 2017/01/04 Adocia announces its financial calendar for 2017 2016 Download 2016/12/16 Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro 2016/11/10 Adocia to Participate in Upcoming Investor Conferences 2016/11/07 Adocia receives the 1st prize for ‘Profitable Growth’ and the 3rd ‘Technology Fast 50’ prize as part of the 2016 Deloitte In Extenso Technology Fast 50 Grand Rhône Alpes 2016/10/27 Adocia Announces Positive Topline Results from a Phase 1b Clinical Trial Measuring the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 2016/10/12 Adocia announces third quarter 2016 financial results 2016/09/22 Adocia received the EY Global Company Award for the Auvergne Rhône-Alpes region 2016/09/20 Adocia launches a new clinical study of BioChaperone® Combo, its combination of long-acting insulin glargine and fast-acting insulin lispro, in people with type 2 diabetes 2016/09/19 Adocia to hold conference call for investors to provide business update and growth perspectives Wednesday September 21st, 2016 at 6 PM (CET) 2016/09/08 Adocia to Present Clinical Data Validating BioChaperone® Technology at the 2016 EASD Annual Meeting 2016/09/07 Adocia announces new BioChaperone program combining a basal insulin and GLP-1s 2016/08/25 Adocia announces topline results of Indian Phase 3 trial of BioChaperone PDGF for diabetic foot ulcer 2016/07/20 Adocia presents first half 2016 financial results 2016/07/05 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets 2016/06/08 Adocia reinforces its focus on diabetes with the launch of a new project: BioChaperone Glucagon 2016/06/06 Adocia to Present Data Validating the Potential of BioChaperone® Technology at the American Diabetes Association® 76th Scientific Sessions 2016/06/02 Adocia to Present at the Jefferies 2016 Global Healthcare Conference 2016/05/31 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects 2016/05/13 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris 2016/05/03 Adocia strengthens its BioChaperone Combo patent portfolio 2016/04/27 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes 2016/04/14 Adocia announces first quarter 2016 results 2016/04/11 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 2016/04/11 Adocia announces the release of its Reference Document, for the year 2015 2016/03/25 ADOCIA confirms its eligibility for the PEA – PME 2016/03/21 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board 2016/03/16 Annual Financial Results 2015 2016/03/14 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes 2016/02/16 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 2016/02/04 Adocia to Present at the 2016 Leerink Global Healthcare Conference 2016/01/29 Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects 2016/01/08 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets 2015 Download 2015/12/16 Adocia announces its financial calendar for 2016 2015/12/15 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 2015/12/11 Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 2015/11/25 Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes 2015/11/19 Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region 2015/11/04 Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes 2015/10/13 ADOCIA Reports Third Quarter 2015 Financial Results 2015/10/06 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy 2015/09/30 Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes 2015/08/27 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes 2015/07/21 Adocia presents financial results for the first half of 2015 highlighting strong growth 2015/07/10 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo 2015/06/26 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes 2015/06/15 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices 2015/05/28 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 2015/05/26 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) 2015/05/04 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 2015/04/29 Adocia is now integrated into the EnterNext Tech 40 Index 2015/04/20 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon 2015/04/14 Adocia announces first quarter 2015 results 2015/03/16 Adocia will present its 2014 annual results and its perspectives of growth during a conference call 2015/03/10 Adocia reports a strengthened cash position and intensifies clinical development 2015/03/05 Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly 2015/02/17 ADOCIA: annual revenue and net cash position for 2014 2015/02/10 Adocia: modification of the means allocated to the liquidity agreement 2015/02/05 Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet 2015/01/20 Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation 2015/01/09 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets 2014 Download 2014/12/29 ADOCIA announces its financial calendar for 2015 2014/12/22 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow 2014/12/19 Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2014/10/16 ADOCIA Announces Third-quarter Financial 2014 Results 2014/09/30 ADOCIA Wins Frost & Sullivan 2014 Technology Innovation Leadership Award in the Therapeutic Proteins Industry 2014/09/09 Adocia Reports Positive Preliminary Results from Dose Response Clinical Study of Ultra-fast acting BioChaperone® Lispro U100 in Patients with Type 1 Diabetes 2014/08/25 Adocia Launches Phase III Clinical Study in India Of Treatment for Diabetic Foot Ulcer 2014/07/24 Adocia Reports Operational and Financial Results for the First Half of 2014 2014/07/09 Adocia Announces Approval to Start a Phase IIa Clinical Study of HinsBet®, its Fast-acting Human Insulin, in Type 1 Diabetes 2014/06/24 ADA 74th Edition: Poster of positive results of Bio Chaperone® Lispro (english only) 2014/06/16 ADA 74th Edition: Poster of positive results of BioChaperone® Combo (english only) 2014/06/10 Adocia Announces Positive Preclinical Results for a Concentrated Ultra-Fast insulin, BioChaperone® Lispro U300 2014/06/04 Adocia to Present Successful Clinical Results for BioChaperone® Lispro and BioChaperone® Combo at the American Diabetes Association 74th Scientific Sessions on June 15th 2014 2014/05/27 Adocia initiates ADR program in the United States 2014/05/20 Adocia: PR BC Lispro Initiation of phase 2a 2014/05/19 Adocia Press Release Liquidity Agreement with Kepler 2014/05/06 Termination of Liquidity Agreement with DSF Markets 2014/04/10 Adocia: Ultra Fast Lispro Clinical Results 2014/04/10 Adocia: Revenue Q1 2014 2014/03/26 Gerard Soula Interview – La bourse et la vie (Transcript) 2014/03/20 Adocia: Annual results 2013 2014/03/17 Adocia: confirmation of positive clinical results Combo 2014/02/26 Positive Clinical Results for Combo 2014/02/10 Adocia: Annual revenue of EUR 5.6 M in 2013 2014/01/28 Adocia strengthens its diabetic foot ulcer patent portfolio 2014/01/20 Half year report on Adocia’s liquidity agreement at December 2013 2014/01/06 Adocia launches phase IIa clinical trial for its ultra-fast acting formulation of analog insulin 2013 Download 2013/12/09 Adocia signs an exclusive license on a nanotechnology which improves the efficacy of anti-tumoral agents by targeting their action into tumors 2013/11/13 Adocia announces the initiation of a clinical trial on its combination of the long-acting insulin Glargine and a fast-acting insulin analog 2013/10/24 Adocia announces revenues of EUR 4.7 M for Q3 of 2013 (with no cash impact) and maintained available cash at Eur 22.7 M 2013/10/19 Gérard Soula : interview by Gérald Bouchon, radio Lyon 1ère 2013/09/05 Activity and results for the first half of 2013 2013/07/29 Adocia reacquires exclusive development rights to ultra-fast acting insulin analog. Adocia and Lilly terminate collaboration 2013/07/15 Half Year report on Adocia’s Liquidity agreement with BIL Finance 2013/04/26 Release of 2012 Reference Document (French only) 2013/04/24 Q1 2013 revenues 2013/04/23 Liquidity agreement 2013/04/23 PR Suspension liquidity agreement 2013/03/18 Adocia announces its phase III development program for the treatment of diabetic foot ulcer. This program has been validated by scientific advice from the European Medicines Agency 2013/02/13 ADOCIA reports a revenue multiplied by 2.5 with a strong cash position for 2012 2013/01/07 Adocia announces its financial calendar for 2013 as well as its participation to upcoming investor conferences 2012 Download 2012/10/30 Adocia announces the strong growth of its turnover 2012/10/22 Adocia is extending its intellectual property to new formulations of monoclonal antibodies 2012/10/01 EASD 2012 – 48th Annual Meeting of the European Association for the Study of Diabetes – 1-5 October 2012, Messe Süd, Berlin, Germany 2012/09/12 Bio India International Conference – 12-13 septembre 2012, Grand Hyatt, Mumbai, Inde 2012/09/07 DFSICON 2012 – 11th Annual Meeting of Diabetic Foot Society of India – 7-9 September 2012, Hyderabad, India 2012/09/03 Financial results and business report for the first half of 2012 2012/09/02 WUWHS 2012 – 4th Congress of the World Union of Wound Healing Societies – 2-6 September 2012, Yokohama, Japon 2012/06/13 Adocia announces a strengthened intellectual property on its lead project for its chronic wounds treatment 2012/05/30 Additional contribution to Liquidity Agreement with Dexia Securities France (French only) 2012/04/26 ADOCIA maintains its dynamic growth: revenue of 1st quarter 2012 2012/04/23 ADOCIA reports positive phase II clinical results 2012/04/02 Résultats financiers annuels 2011 – 2011, une étape majeure dans le développement d’ADOCIA 2012/03/15 Liquidity agreement with Dexia Securities France (French only) 2012/03/15 ADOCIA increases the size of its Initial Public Offering to E27.4 million through the partial… NEWS PRESS RELEASES UPCOMING EVENTS A la Une / Spotlight November 23rd, meet Adocia at Investir Day Exhibition, in Paris Dear shareholders and individual investors, Ado... November 14: World Diabetes Day 1 in 11 people in the world suffer from diabete... Home Terms Of Use Privacy Policy Contact Copyright ADOCIA © 2018 Adocia use cookies on the site to analyze site usage and improve your user experience. These cookies are necessary for the proper functioning of the site, and also provide information on how you use the site in order to provide you with optimal navigation, and to help us with our marketing activities. If you delete or disable cookies, you may experience interruptions or problems accessing the site. For more information on the protection of your personal data and the management of cookies, see our Privacy and Cookie Management Policy. ✓ OK, accept all Personalize